[1] |
Reya T, Morrison SJ, Clarke MF, et al. Stem cells, cancer, and cancer stem cells. Nature, 2001, 414(6859):105-111.
|
[2] |
Keysar SB, Jimeno A. More than markers: biological significance of cancer stem cell-defining molecules. Mol Cancer Ther, 2010, 9(9):2450-2457.
|
[3] |
Zhang H, Li SY. Research progression of CD133 as a marker of cancer stem cells. Chin J Cancer, 2010, 29(3):243-247.
|
[4] |
Han ZB, Chen HY, Fan JW, et al. Up-regulation of microRNA-155 promotes cancer cell invasion and predicts poor survival of hepatocellular carcinoma following liver transplantation. J Cancer Res Clin Oncol, 2012, 138(1):153-161.
|
[5] |
Cheng J, Xie HY, Xu X, et al. NDRG1 as a biomarker for metastasis, recurrence and of poor prognosis in hepatocellular carcinoma. Cancer Lett, 2011, 310(1):35-45.
|
[6] |
Schmitz KJ, Sotiropoulos GC, Baba HA, et al. AKR1B10 expression is associated with less aggressive hepatocellular carcinoma: a clinicopathological study of 168 cases. Liver Int, 2011, 31(6):810-816.
|
[7] |
Sun H, Teng M, Liu J, et al. FOXM1 expression predicts the prognosis in hepatocellular carcinoma patients after orthotopic liver transplantation combined with the Milan criteria. Cancer Lett, 2011, 306(2):214-222.
|
[8] |
Yang Z, Zhou L, Wu LM, et al. Overexpression of long non-coding RNA HOTAIR predicts tumor recurrence in hepatocellular carcinoma patients following liver transplantation. Ann Surg Oncol, 2011, 18(5):1243-1250.
|
[9] |
Shmelkov SV, St Clair R, Lyden D, et al. AC133/CD133/Prominin-1. Int J Biochem Cell Biol, 2005, 37(4):715-719.
|
[10] |
Shinto E, Hashiguchi Y, Ueno H, et al. Pretreatment CD133 and cyclooxygenase-2 expression as the predictive markers of the pathological effect of chemoradiotherapy in rectal cancer patients. Dis Colon Rectum, 2011, 54(9):1098-1106.
|
[11] |
Yang JP, Liu Y, Zhong W, et al. Chemoresistance of CD133+ cancer stem cells in laryngeal carcinoma. Chin Med J, 2011, 124(7):1055-1060.
|
[12] |
Chiba T, Kita K, Zheng YW, et al. Side population purified from hepatocellular carcinoma cells harbors cancer stem cell-like properties. Hepatology, 2006, 44(1):240-251.
|
[13] |
Ma S, Chan KW, Hu L, et al. Identification and characterization of tumorigenic liver cancer stem/progenitocells. Gastroenterology, 2007, 132(7):2542-2556.
|
[14] |
Yin S, Li J, Hu C, et al. CD133 positive hepatocellular carcinoma cells possess high capacity for tumorigenicity. Int J Cancer, 2007, 120(7):1444-1450.
|
[15] |
Li YF, Xiao B, Tu SF, et al. Cultivation and identification of colon cancer stem cell-derived spheres from the Colo205 cell line. Braz J Med Biol Res, 2012, 45(3):197-204.
|
[16] |
Catalano V, Di Franco S, Iovino F, et al. CD133 as a target for colon cancer. Expert Opin Ther Targets, 2012, 16(3):259-267.
|
[17] |
Lee HJ, You DD, Choi DW, et al. Significance of CD133 as a cancer stem cell markers focusing on the tumorigenicity of pancreatic cancer cell lines. J Korean Surg Soc, 2011, 81(4):263-270.
|
[18] |
Choijamts B, Jimi S, Kondo T, et al. CD133+cancer stem cell-like cells derived from uterine carcinosarcoma (malignant mixed Müllerian tumor). Stem Cells, 2011, 29(10):1485-1495.
|
[19] |
Rentala S, Mangamoori LN. Isolation, characterization and mobilization of prostate cancer tissue derived CD133+ MDR1+ cells. J Stem Cells, 2010, 5(2):75-81.
|
[20] |
Gambelli F, Sasdelli F, Manini I, et al. Identification of cancer stem cells from human glioblastomas: growth and differentiation capabilities and CD133/prominin-1 expression. Cell Biol Int, 2012, 36(1):29-38.
|
[21] |
Janikova M, Skarda J, Dziechciarkova M, et al. Identification of CD133+/nestin+putative cancer stem cells in non-small cell lung cancer. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub, 2010, 154(4):321-326.
|
[22] |
Curley MD, Therrien VA, Cummings CL, et al. CD133 expression defines a tumor initiating cell population in primary human ovarian cancer. Stem Cells, 2009, 27(12):2875-2883.
|
[23] |
Cox CV, Diamanti P, Evely RS, et al. Expression of CD133 on leukemia-initiating cells in childhood ALL. Blood,2009, 113(14):3287-3296.
|
[24] |
Galizia G, Gemei M, Del Vecchio L, et al. Combined CD133/CD44 expression as a prognostic indicator of disease-free survival in patients with colorectal cancer. Arch Surg, 2012, 147(1):18-24.
|
[25] |
Zhang J, Guo X, Chang DY, et al. CD133 expression associated with poor prognosis in ovarian cancer. Mod Pathol, 2012, 25(3):456-464.
|
[26] |
Sasaki A, Kamiyama T, Yokoo H, et al. Cytoplasmic expression of CD133 is an important risk factor for overall survival in hepatocellular carcinoma. Oncol Rep, 2010, 24(2):537-546.
|
[27] |
Song W, Li H, Tao K, et al. Expression and clinical significance of the stem cell marker CD133 in hepatocellular carcinoma. Int J Clin Pract, 2008, 62(8):1212-1218.
|
[28] |
Na DC, Lee JE, Yoo JE, et al. Invasion and EMT-associated genes are up-regulated in B viral hepatocellular carcinoma with high expression of CD133-human and cell culture study. Exp Mol Pathol, 2011, 90(1):66-73.
|
[29] |
Piao LS, Hur W, Kim TK, et al. CD133+ liver cancer stem cells modulate radioresistance in human hepatocellular carcinoma. Cancer Lett, 2012, 315(2):129-137.
|
[30] |
Smith LM, Nesterova A, Ryan MC, et al. CD133/prominin-1 is a potential therapeutic target for antibody-drug conjugates in hepatocellular and gastric cancers. Br J Cancer, 2008, 99(1):100-109.
|